Zanamivir
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Zanamivir: From Influenza to Pyelonephritis
One-Sentence Summary
Zanamivir is a neuraminidase inhibitor, originally used to treat influenza. The TxGNN model predicts it may be effective for pyelonephritis, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Influenza |
| Predicted New Indication | Pyelonephritis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 |
| US Market Status | Cancelled only (the single NDA is cancelled) |
| Number of NDAs | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the data compiled for this report. Based on known information, zanamivir is a viral neuraminidase inhibitor, and its efficacy in influenza has been established.
A plausible mechanistic link to pyelonephritis is hard to find. Pyelonephritis is mostly caused by bacteria such as E. coli, not by viruses. Bacteria do produce neuraminidases (sialidases) that may contribute to virulence, but zanamivir has little established activity against them, so this idea is speculative.
Practical feasibility is also limited. Systemic exposure from the inhaled formulation is low, and an intravenous form is not widely marketed, which makes treating a urinary tract infection difficult. The high score is likely an artifact of the knowledge graph, for example connections through infection-related nodes.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA021036 (cancelled) | RELENZA (GlaxoSmithKline LLC) | Powder | Not listed in the compiled data |
Safety Considerations
- Disease associations flagged in the knowledge graph (not label text): epilepsy, chronic obstructive pulmonary disease (including severe early-onset COPD), bronchial disease, and delirium.
- Drug Interactions (8 recorded):
- Insulin human (inhalation, rapid acting): Moderate
- Clarithromycin, loratadine, montelukast, ketotifen, fexofenadine, ibuprofen, diclofenac: severity level unknown
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a high model score. There are no clinical trials or literature, no plausible mechanism against bacterial pyelonephritis, and the only US license is cancelled. The score is likely a knowledge-graph artifact.
To proceed, the following is needed:
- Detailed mechanism of action data, including any evidence of zanamivir activity against bacterial neuraminidases
- Preclinical evidence in relevant urinary tract infection models
- Package insert warnings and contraindications
- Pharmacokinetic data on urinary exposure and feasible routes of administration, since the inhaled form gives low systemic exposure
- A review of how the knowledge graph produced this prediction
Note on the second prediction (disorder of tyrosine metabolism, score 99.02%): This candidate is also at Evidence Level L5 with a Hold recommendation. The three retrieved publications all concern influenza neuraminidase inhibitors (oseltamivir resistance, an SPR inhibition assay, and an N294S neuraminidase mutation). None addresses tyrosine metabolism, and there is no apparent mechanistic link. This is most likely a prediction artifact.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.